Sunday, August 31, 2014

Inhibiting inflammatory enzyme after heart attack does not reduce risk of subsequent event

[

| E-mail

]


Contact: Jessica Makijmaki3@partners.org

617-525-6373The JAMA Network Journals


In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated…

Inhibiting inflammatory enzyme after heart attack does not reduce risk of subsequent event




No comments:

Post a Comment